Mkrs.Bo
MKRS.BO maintains a conservative capital structure with a debt-to-equity ratio of 0.07, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 3.22, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's operating cash flow is negative at -40,789,000 INR, which may raise concerns about its ability to sustain operations without external financing. In terms of profitability, MKRS.BO reports a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.06%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks. Looking ahead, MKRS.BO is projected to experience a modest growth trajectory, with no specific numeric deltas provided in the outlo
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MKRS.BO maintains a conservative capital structure with a debt-to-equity ratio of 0.07, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 3.22, suggesting it can cover short-term obligations but with limited excess capacity. However, the company's operating cash flow is negative at -40,789,000 INR, which may raise concerns about its ability to sustain operations without external financing.
In terms of profitability, MKRS.BO reports a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.06%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks.
Looking ahead, MKRS.BO is projected to experience a modest growth trajectory, with no specific numeric deltas provided in the outlook. However, the company's free cash flow of 117,523,000 INR indicates some capacity for reinvestment or shareholder returns. The absence of a detailed growth plan or segment-specific outlook suggests limited visibility into future performance.
The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which could signal potential liquidity constraints. The company's dilution risk is assessed as low, with no near-term pressure expected, and no recent dilutive events reported. However, the negative operating cash flow and reliance on free cash flow for operations may necessitate close monitoring of capital structure decisions.
Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of recent material events or disclosures suggests a relatively stable but unremarkable business environment for MKRS.BO.
- MKRS.BO has a low debt-to-equity ratio but faces liquidity concerns due to negative operating cash flow.
- The company's ROE and ROA are below industry medians, indicating suboptimal capital and asset efficiency.
- Revenue and geographic diversification data are not disclosed, suggesting potential concentration risks.
- Free cash flow is positive, but the company's growth outlook lacks specificity and segment-level detail.
- Dilution risk is low, but liquidity risk remains a concern due to negative net cash after debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MKRS.BO Market data — financials · 2026-05-28